Original Article

You have full text access to this OnlineOpen article

Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma†‡

A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group

  1. Howard M. Katzenstein MD1,§,*,
  2. Kay W. Chang MD2,
  3. Mark Krailo PhD3,
  4. Zhengjia Chen PhD4,
  5. Milton J. Finegold MD5,
  6. Jon Rowland MD, PhD6,
  7. Marleta Reynolds MD7,
  8. Alberto Pappo MD5,
  9. Wendy B. London PhD8,
  10. Marcio Malogolowkin MD9

Article first published online: 7 OCT 2009

DOI: 10.1002/cncr.24667

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5828–5835, 15 December 2009

Additional Information

How to Cite

Katzenstein, H. M., Chang, K. W., Krailo, M., Chen, Z., Finegold, M. J., Rowland, J., Reynolds, M., Pappo, A., London, W. B. and Malogolowkin, M. (2009), Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. Cancer, 115: 5828–5835. doi: 10.1002/cncr.24667

Author Information

  1. 1

    Department of Pediatrics, Aflac Cancer Center of Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia

  2. 2

    Department of Otolaryngology, Lucile Packard Children's Hospital at Stanford, Palo Alto, California

  3. 3

    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

  4. 4

    Group Operations Center, Children's Oncology Group Statistics and Data Center, Arcadia, California

  5. 5

    Departments of Pathology and Hematology/Oncology, Texas Children' Cancer Center, Baylor College of Medicine, Houston, Texas

  6. 6

    Department of Pathology, Children's Hospital of Oakland, Oakland, California

  7. 7

    Department of Surgery, Northwestern University and Children's Memorial Hospital, Chicago, Illinois

  8. 8

    Department of Statistics, University of Florida, Children's Oncology Group Data Center, Gainesville, Florida

  9. 9

    Department of Pediatrics, Children's Hospital, Los Angeles, California

  1. §

    Fax: (626) 445-4334

*Children's Oncology Group, 440 East Huntington Drive, Suite 400, Arcadia, CA 91066

  1. †

    See editorial on pages 5623–6, this issue.

  2. ‡

    We are extremely grateful for the hard work and diligence of the clinical research associates of our member institutions for data collection and to the Children' Oncology Group Publications Office for editorial assistance.

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 7 OCT 2009
  3. Manuscript Accepted: 13 MAR 2009
  4. Manuscript Revised: 11 MAR 2009
  5. Manuscript Received: 30 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (203K)

Keywords:

  • hepatoblastoma;
  • amifostine;
  • hearing;
  • ototoxicity

Amifostine in the doses and schedule used in Children's Oncology Group Study P9645 failed to significantly reduce the incidence of hearing loss and other platinum-induced toxicities in patients with hepatoblastoma.

Abstract

BACKGROUND:

The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum-containing regimens in children with hepatoblastoma (HB).

METHODS:

Patients were enrolled on P9645 beginning in March of 1999. Patients who had stage I/II disease received treatment with 4 cycles of combined cisplatin, 5-fluorouracil, and vincristine (C5V) with or without amifostine. Patients who had stage III/IV disease were randomized to receive treatment with 6 cycles of either C5V with or without amifostine or carboplatin alternating with cisplatin (CC) with or without amifostine. Patients who were randomized to receive amifostine were given a dose of 740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent.

RESULTS:

Eighty-two patients were considered in a special interim analysis of the incidence of toxicity. The disease outcome for patients who received amifostine was similar to the outcome for patients who did not receive amifostine (P = .22). The incidence of significant hearing loss (>40 dB) was similar for patients who did or did not receive amifostine (38% [14 of 37 patients] vs 38% [17 of 45 patients], respectively; P = .68). There were no differences in the incidence of renal or bone marrow toxicities evaluated. Patients who received amifostine had a higher incidence of hypocalcemia (5% vs 0.5%; P = .00006).

CONCLUSIONS:

Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum-induced toxicities in patients with HB. Cancer 2009. © 2009 American Cancer Society.

View Full Article (HTML) Get PDF (203K)